0001106838
false
0001106838
2023-08-14
2023-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 14, 2023
SONNET
BIOTHERAPEUTICS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-35570 |
|
20-2932652 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
100
Overlook Center, Suite 102 |
|
|
Princeton,
New Jersey |
|
08540 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (609) 375-2227
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.0001 Par Value |
|
SONN |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
August 14, 2023, Sonnet BioTherapeutics Holdings, Inc. (the “Registrant”) issued a press release regarding its financial
results for the three months ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated
by reference herein.
Forward-Looking
Statements
This
report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities laws.
Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,”
“plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites of such
words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks
and uncertainties that exist in the Registrant’s operations and business environment, which may be beyond the Registrant’s
control, and which may cause actual results, performance or achievements to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are
statements that could be forward-looking statements. For example, forward-looking statements include, without limitation: statements
regarding prospects for additional customers; market forecasts; projections of earnings, revenues, synergies, accretion or other financial
information; and plans, strategies and objectives of management for future operations. The risks and uncertainties referred to above
include, but are not limited to, risks detailed from time to time in the Registrant’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year ended September 30, 2022. These risks could cause actual results to
differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Registrant. Forward-looking statements
represent the judgment of management of the Registrant regarding future events. Although the Registrant believes that the expectations
reflected in such forward-looking statements are reasonable at the time that they are made, the Registrant can give no assurance that
such expectations will prove to be correct. Unless otherwise required by applicable law, the Registrant assumes no obligation to update
any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events
or otherwise.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Sonnet
BioTherapeutics Holdings, Inc. |
|
a
Delaware corporation |
|
(Registrant) |
|
|
Date:
August 14, 2023 |
By: |
/s/
Pankaj Mohan, Ph.D. |
|
Name: |
Pankaj
Mohan, Ph.D. |
|
Title: |
Chief
Executive Officer |
Exhibit
99.1
Sonnet
BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
| ● | Combination
study of SON-1010 with Roche’s atezolizumab (Tecentriq®) has been initiated in
Australia |
| | |
| ● | First
SON-1010 Phase 1 study has been completed and comparison of the human pharmacokinetic data
supports targeting of tumor tissue |
| | |
| ● | Early
safety data from the SON-080 trial in CIPN is expected after the study’s Data Safety
Monitoring Board (DSMB) convenes, prior to calendar year end |
| | |
| ● | Collaboration
with Janssen, where in vitro and in vivo efficacy of SON-1010, SON-1210, and SON-1410 are
being evaluated in combination with certain Janssen cell therapy assets, remains ongoing |
PRINCETON,
NJ / ACCESSWIRE / August 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”),
a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months
ended June 30, 2023 and provided a business update.
“Sonnet
continues to successfully forge ahead with our pipeline development,” said Pankaj Mohan, Ph.D., Founder and CEO. “The initiation
of the clinical trial with SON-1010 and Roche’s atezolizumab is an important event for the company and for our mission to innovate
potentially life-saving treatments for cancer patients. Further, our collaboration with Janssen is ongoing and we hope to have information
to share with investors in the coming quarters. During the quarter, we were able to present important data from our SON-1010 clinical
trials at the American Association for Cancer Research (AACR), as well as deliver two FHAB technology presentations at the
Cytokine-Based Drug Development Summit. As part of our financing initiative, we completed a $2.25 million registered direct offering
and concurrent private placement in June, which was strategically executed to result in the Company remaining in compliance with the
Nasdaq continued listing requirement in shareholder equity. Our plan to extend our cash runway into the 2024 calendar year remains in
place and involves receiving R&D tax credits from New Jersey and Australia.”
“We
are quite pleased with the progress of our clinical programs,” said Dr. Richard Kenney, CMO. “Both of the SON-1010 Phase
1 first-in-human studies are wrapping up, with final data analysis in the healthy volunteer study and ongoing enrollment of the highest
dose cohort in the cancer study, which will establish the maximum tolerated dose. The latter will be expanded in platinum-resistant ovarian
cancer (PROC) to confirm the clinical benefit in that population at the maximum tolerated dose before moving on to the next study. Comparing
the pharmacokinetics for the two studies shows a compelling difference in SON-1010 excretion patterns that suggests the FHAB
molecule is being taken up and retained by the tumors, as it was designed to do. We are starting our combination study using SON-1010
with atezolizumab in Australia and are working to enroll several cohorts by the end of this year. Regarding the SON-080 trial in CIPN,
we continue to anticipate a DSMB meeting this calendar year, after which we will be in a position to disclose the early safety findings.”
FY
2023 Third Quarter and Recent Corporate Updates
Sonnet
provided the following corporate updates:
| ● | On
April 18, 2023, we presented additional data from the SB101 study of SON-1010 at the 2023
AACR Annual Meeting. SB101 is a single-ascending dose (SAD) trial in adult patients with
advanced solid tumors that commenced in the second quarter of 2022 and is currently enrolling
the final dose cohort. Of the 15 patients from the first five cohorts of SB101 evaluable
for follow-up at this latest cutoff, 9 had stable disease at the first follow-up scan, 4
of which were already progressing at study entry. At the four-month follow-up, 5 of 14 patients
remained stable at the second scan, suggesting clinical benefit of SON-1010 in 36% of patients.
As an example, the very first patient dosed, who has an aggressive endometrial sarcoma, had
target tumor shrinkage with complete resolution of ascites at one point and has been clinically
stable for over a year. SON-1010 has been safe and tolerable at all doses tested to date.
Adverse events have generally been mild/moderate and transient in nature, with no study discontinuations
for safety reasons. In addition, adverse effects have been less numerous and less intense
with subsequent doses. The geomean half-life (t½) of SON-1010 was 113 hours in SB101
and 122 hours in SB102, compared to the published value of 12 hours for recombinant IL-12
observed in prior studies. Comparison of the PK curves between the two studies suggests that
SON-1010 may be targeting tumors, as it was designed to do. Cytokine analysis following each
dose revealed controlled and prolonged induction of interferon gamma (IFNγ) that peaked
at 24 to 48 hours and returned to baseline after 2 to 4 weeks, which may improve tumor control.
A small increase in IL-10 was observed with each dose, as might be expected in response to
IFNγ. There was either a minimal or no signal for IL-1β, IL-6, IL-8, and TNFα
and no indication of any potential for cytokine release syndrome (CRS) at these doses. |
| | |
| ● | The
ex-U.S. Phase 1b/2a study with SON-080 in CIPN remains ongoing. Pursuant to a license agreement
the Company entered with New Life Therapeutics Pte, Ltd. (“New Life”) of Singapore
in May 2021, Sonnet and New Life will be jointly responsible for developing SON-080 in DPN.
The DSMB overseeing the study is expected to meet during the third calendar quarter of 2023.
Following the completion of the DSMB review, we anticipate announcing initial safety data
from the CIPN study and will consider initiating a Phase 2 study in DPN. |
| | |
| ● | In
February 2023, the Company announced the successful completion of two IND-enabling toxicology
studies with SON-1210 in non-human primates. SON-1210 (IL12- FHAB -IL15), Sonnet’s
lead bispecific construct, combines the FHAB with fully human IL-12 and fully
human IL-15. Sonnet is prepared to initiate the regulatory authorization process for SON-1210
in 2023, pending the outcome of any partnering activity. |
| | |
| ● | Preclinical
development continues for SON-1410 (IL18-FHAB-IL12), Sonnet’s proprietary
bispecific combination of IL-18 and IL-12, where cell line development for GMP application
is underway. After some delays in 2023, process development activities will continue into
2024, with the potential to generate a drug suitable for human studies. |
“Our
mission to advance the company’s pipeline while containing our costs remains in place, and we continue to be confident in the potential
of our FHAB technology. We are looking forward to our future data releases,” commented Jay Cross, CFO.
FY
2023 Third Quarter Ended June 30, 2023 Financial Results
| ● | As
of June 30, 2023, Sonnet had $7.0 million cash on hand. |
| | |
| ● | Research
and development expenses were $2.4 million for the three months ended June 30, 2023, compared
to $5.6 million for the three months ended June 30, 2022. The decrease of $3.2 million was
primarily due to the establishment of cost savings by transitioning product development activities
to cost advantaged locations such as India and Australia and by reducing expenditures on
tertiary programs such as SON-3015, which has been placed on a development hold, as well
as a decrease in share-based compensation expense. |
| | |
| ● | General
and administrative expenses were $1.5 million and $2.3 million for the three months ended
June 30, 2023, and 2022, respectively. The decrease in general and administrative expenses
is a result of cost-saving initiatives. |
About
Sonnet BioTherapeutics Holdings, Inc.
Sonnet
BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific
action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment
(scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. Sonnet’s FHAB
was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy
of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range
of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Forward-Looking
Statements
This
press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section21E
of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the offering,
the closing of the offering, the amount and anticipated use of proceeds from the offering, the timing of an IND submission, the Company’s
product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results
of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate
and management’s current beliefs and assumptions.
These
statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,”
“intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,”
“should,” “would” and similar expressions and the negatives of those terms. These statements relate to future
events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of
this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise.
Sonnet
BioTherapeutics Investor Contact:
Jack
Yauch
Solebury
Strategic Communications
862-754-1024
jyauch@soleburystrat.com
Sonnet
BioTherapeutics Holdings, Inc.
Consolidated
Balance Sheets
(unaudited)
| |
June 30, | | |
September 30, | |
| |
2023 | | |
2022 | |
Assets | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash | |
$ | 7,021,071 | | |
$ | 3,052,879 | |
Incentive tax receivable | |
| 749,169 | | |
| 717,305 | |
Prepaid expenses and other current assets | |
| 1,862,683 | | |
| 1,643,743 | |
Total current assets | |
| 9,632,923 | | |
| 5,413,927 | |
Property and equipment, net | |
| 36,577 | | |
| 46,211 | |
Operating lease right-of-use asset | |
| 209,944 | | |
| 256,594 | |
Deferred offering costs | |
| — | | |
| 113,280 | |
Other assets | |
| 155,366 | | |
| — | |
Total assets | |
$ | 10,034,810 | | |
$ | 5,830,012 | |
Liabilities and stockholders’ equity (deficit) | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Related-party notes payable | |
$ | — | | |
$ | 748 | |
Accounts payable | |
| 3,024,441 | | |
| 4,752,340 | |
Accrued expenses and other current liabilities | |
| 3,315,404 | | |
| 3,193,972 | |
Operating lease liability | |
| 70,446 | | |
| 51,328 | |
Deferred income | |
| 55,882 | | |
| 166,431 | |
Total current liabilities | |
| 6,466,173 | | |
| 8,164,819 | |
Operating lease liability | |
| 150,185 | | |
| 203,912 | |
Total liabilities | |
| 6,616,358 | | |
| 8,368,731 | |
Commitments and contingencies | |
| | | |
| | |
Stockholders’ equity (deficit): | |
| | | |
| | |
Preferred stock; $0.0001 par value: 5,000,000 shares authorized. No shares issued or outstanding | |
| — | | |
| — | |
Common stock; $0.0001 par value: 125,000,000 shares authorized; 38,389,648 and 5,544,528 issued and outstanding at June 30, 2023 and September 30, 2022 | |
| 3,839 | | |
| 554 | |
Additional paid-in capital | |
| 109,981,627 | | |
| 88,871,786 | |
Accumulated deficit | |
| (106,567,014 | ) | |
| (91,411,059 | ) |
Total stockholders’ equity (deficit) | |
| 3,418,452 | | |
| (2,538,719 | ) |
Total liabilities and stockholders’ equity (deficit) | |
$ | 10,034,810 | | |
$ | 5,830,012 | |
See
10-Q filed today for notes to consolidated financial statements
Sonnet
BioTherapeutics Holdings, Inc.
Consolidated
Statements of Operations
(unaudited)
| |
Three Months Ended June 30, | | |
Nine Months Ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Collaboration revenue | |
$ | 36,850 | | |
$ | 62,071 | | |
$ | 110,550 | | |
$ | 287,190 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 2,409,471 | | |
| 5,648,952 | | |
| 9,972,055 | | |
| 16,320,090 | |
General and administrative | |
| 1,542,689 | | |
| 2,280,345 | | |
| 5,330,967 | | |
| 6,259,494 | |
Total operating expenses | |
| 3,952,160 | | |
| 7,929,297 | | |
| 15,303,022 | | |
| 22,579,584 | |
Loss from operations | |
| (3,915,310 | ) | |
| (7,867,226 | ) | |
| (15,192,472 | ) | |
| (22,292,394 | ) |
Foreign exchange (loss) gain | |
| (31,432 | ) | |
| (9,794 | ) | |
| 36,517 | | |
| 5,894 | |
Net loss | |
$ | (3,946,742 | ) | |
$ | (7,877,020 | ) | |
$ | (15,155,955 | ) | |
$ | (22,286,500 | ) |
Per share information: | |
| | | |
| | | |
| | | |
| | |
Net loss per share, basic and diluted | |
$ | (0.13 | ) | |
$ | (1.82 | ) | |
$ | (0.86 | ) | |
$ | (5.17 | ) |
Weighted average shares outstanding, basic and diluted | |
| 29,376,018 | | |
| 4,330,489 | | |
| 17,568,549 | | |
| 4,314,635 | |
See
10-Q filed today for notes to consolidated financial statements
SOURCE:
Sonnet BioTherapeutics, Inc.
v3.23.2
Cover
|
Aug. 14, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 14, 2023
|
Entity File Number |
001-35570
|
Entity Registrant Name |
SONNET
BIOTHERAPEUTICS HOLDINGS, INC.
|
Entity Central Index Key |
0001106838
|
Entity Tax Identification Number |
20-2932652
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
100
Overlook Center
|
Entity Address, Address Line Two |
Suite 102
|
Entity Address, City or Town |
Princeton
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
08540
|
City Area Code |
(609)
|
Local Phone Number |
375-2227
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.0001 Par Value
|
Trading Symbol |
SONN
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Sonnet BioTherapeutics (NASDAQ:SONN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sonnet BioTherapeutics (NASDAQ:SONN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024